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A pan-cancer genome-wide analysis reveals
tumour dependencies by induction of
nonsense-mediated decay
Zhiyuan Hu1,2,3, Christopher Yau3,4 & Ahmed Ashour Ahmed1,2
Nonsense-mediated decay (NMD) eliminates transcripts with premature termination codons.
Although NMD-induced loss-of-function has been shown to contribute to the genesis of
particular cancers, its global functional consequence in tumours has not been characterized.
Here we develop an algorithm to predict NMD and apply it on somatic mutations reported in
The Cancer Genome Atlas. We identify more than 73K mutations that are predicted to elicit
NMD (NMD-elicit). NMD-elicit mutations in tumour suppressor genes (TSGs) are associated
with signiﬁcant reduction in gene expression. We discover cancer-speciﬁc NMD-elicit
signatures in TSGs and cancer-associated genes. Our analysis reveals a previously
unrecognized dependence of hypermutated tumours on hypofunction of genes that are
involved in chromatin remodelling and translation. Half of hypermutated stomach
adenocarcinomas are associated with NMD-elicit mutations of the translation initiators
LARP4B and EIF5B. Our results unravel strong therapeutic opportunities by targeting tumour
dependencies on NMD-elicit mutations.
DOI: 10.1038/ncomms15943 OPEN
1Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DU, UK. 2 Nufﬁeld Department of Obstetrics and Gynaecology, University of
Oxford, Oxford OX3 9DU, UK. 3Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK. 4 Centre for Computational Biology,
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK. Correspondence and requests for materials should be
addressed to C.Y. (email: c.yau@bham.ac.uk) or to A.A.A. (email: ahmed.ahmed@obs-gyn.ox.ac.uk).
NATURE COMMUNICATIONS | 8:15943 | DOI: 10.1038/ncomms15943 | www.nature.com/naturecommunications 1
N
onsense-mediated decay (NMD) is a physiological cellular
surveillance system that degrades abnormal mRNAs with
premature termination codons (PTCs)1. PTCs are known
to be involved in about one-third of all genetic diseases2 and in
cancer. Because NMD leads to signiﬁcant loss of expression3, it
results in loss-of-function (LoF) of the affected genes and,
therefore, a considerable contribution to the genesis of diseases4.
An example of this is how the inactivation of tumour suppressor
genes (TSGs) harbouring PTCs through NMD is thought to
contribute to cancer initiation5–7. Therefore, the inhibition of
NMD has been proposed as a promising therapeutic modality in
cancer4. However, the extent to which NMD contributes to cancer
progression has remained poorly understood as this requires the
systematic identiﬁcation of genes with PTCs and knowledge of the
rules that govern whether or not NMD is likely to occur. Studies
have focused predominantly on whether single-nucleotide variants
were predicted to generate a PTC but have not attempted to
predict the effect of frameshift mutations. For example, a recent
study showed that TSGs harboured more PTCs that resulted from
single-nucleotide variants leading to stop codons compared to
other genes8. Recent work has validated the previously known rules
for predicting whether a mutation is likely to elicit NMD
(NMD-elicit) or not (NMD-escape)5, but the global impact of
NMD-elicit mutations on cancer has remained unexplored.
In this work we used three recently validated rules5 to predict
whether a mutation that may result in a PTC is NMD-elicit or
NMD-escape (Fig. 1a). For a mutation to elicit NMD, three
conditions are thought to be required. The ﬁrst condition is that
the PTC should be more than 50–54 bp upstream of the last
exon–exon junction9. The second is that the targeted gene has to
comprise at least two exons10, and the last is that the PTC should
be more than 200 bp downstream of the start codon. These
three rules can explain up to 80% of the decreased expression
of the mutated genes5. The analysis of over 1 million somatic
mutations across 24 cancers from The Cancer Genome Atlas
(TCGA) predicts 73,855 NMD-elicit mutations and provides a
comprehensive landscape of NMD targeting in 7,725 genomes and
corresponding transcriptomes. NMD compromises the expression
of mutated TSGs, which may facilitate the initiation or progression
of cancers. In contrast, NMD-elicit mutations in non-TSGs cluster
in particular pathways to promote a phenotypic effect.
Results
Pan-cancer analysis for discovery of NMD-elicit mutations. To
classify TCGA mutations to NMD-elicit, NMD-escape or others,
we developed a prediction algorithm based on the three afore-
mentioned rules of eliciting NMD (Fig. 1a,b). For each mutation,
the algorithm deﬁned the open reading frames (ORFs) of the
affected gene, located the ﬁrst termination codon in the ORF and
computed the distance of the codon from the last exon–exon
junction. We applied our prediction algorithm to all reported
somatic mutations from 24 cancers and predicted 73,855 (6%)
NMD-elicit mutations (Supplementary Data 1). Unexpectedly, our
analysis indicated that only two-thirds of the mutations that were
annotated by TCGA as nonsense mutations (NMs) or frameshift
indels were actually predicted to be NMD-elicit mutations (Fig. 1c).
To validate our classiﬁer, we next compared the expression
levels of NMD-elicit frameshift or NMs with other mutations.
Overall, the predicted NMD-elicit mutations had signiﬁcantly
lower expression compared to NMD-escape, non-PTC-harbouring
or silent mutations (median ratio of relative expression of variant
(REV; see Methods)¼ 0.54, Po2.2e 16, one-sided t-test and
Fig. 1d). Importantly, NMD-escape mutations were not associated
with a reduction in the expression of the affected genes compared
to silent mutations (median ratio of REV¼ 1, P¼ 0.1, one-side
t-test). Of note, stomach adenocarcinoma (STAD), kidney cancer
(KIRP) and colon cancer (COAD) had a disproportionately higher
number of NMD-elicit mutations, compared to other cancers
with similar mutation frequency (Po0.007, by generalized linear
regression; Fig. 1e). These results strongly suggest that NMD plays
an important role in contributing to the LoF of the affected genes
in cancer by loss of expression.
TSGs are frequently inactivated by NMD. We observed that not
all NMD-elicit mutations were associated with a similar
magnitude of reduction in gene expression. In addition, NMD-
elicit mutations seemed to target particular genes at higher
frequency than others. For example, the two genes that were most
widely affected by NMD-elicit mutations were the TSGs TP53
(23 cancer types affected) and NF1 (22 cancer types affected).
However, the frequency of NMD-elicit mutations appears to be
lower than other LoF mutations. For example, NMD-elicit TP53
mutations occurred in 8.8% of all cancer samples (n¼ 7,725), while
missense non-synonymous mutations in the same gene occurred in
22.2% of samples. NMD-elicit mutations in these genes are
associated with a signiﬁcant reduction in gene expression (median
ratio of REV¼ 0.07 for NF1, 0.06 for TP53; Po2.2e 16, one-side
Mann–Whitney–Wilcoxon (MWW) test and Fig. 2a). To formally
evaluate these two factors (frequency and the magnitude of NMD-
associated reduction in expression), we developed a score to
measure the magnitude of NMD-associated reduction in expres-
sion (z-score, see Methods). We conducted a global analysis of all
reported mutations in TCGA and observed that the NMD-elicit
mutations that had the lowest z-scores (highest magnitude of
reduction) and the most frequency tended to occur in known TSGs
or the previously reported signiﬁcantly mutated genes (SMGs) in
cancer11 (Supplementary Fig. 1). The overall prevalence of
NMD-elicit mutations in TSGs12 was 29% (2,206/7,725; range:
5–60%). In uterine corpus endometrioid carcinoma (UCEC),
bladder urothelial carcinoma (BLCA) and stomach cancer (STAD),
more than half of cases had NMD-elicit mutations within TSGs
(Fig. 2b). The list of TSGs or SMGs with highly frequent
NMD-elicit mutations varied according to the tumour types
(Fig. 2c and Table 1). For example, the ATRX gene frequently
harbours NMD-elicit mutations in low grade glioma and sarcoma.
APC is often affected by NMD-elicit mutations in colon cancer
(COAD) and rectal cancer (READ). Of particular note is that
BLCA is uniquely affected by KDM6A NMD-elicit mutations when
compared with other tumour types.
Overall, NMD-elicit mutations in TSGs were associated with
signiﬁcantly lower z-scores compared to NMD-elicit mutations in
other genes (mean ratio¼ 0.29/0.39, Po2.2e 16, one-sided
t-test, Supplementary Fig. 2). To evaluate the potential reason for
this, we tested the co-occurrence between NMD-elicit mutations
and chromosomal deletions at the affected loci. We observed a
strong association between NMD-elicit mutations in TSGs and
deletions in the same locus (Supplementary Fig. 3a). Thus, the
profound reduction in gene expression at TSGs is most probably
the result of NMD of the mutated allele and deletion of the
wild-type allele. Importantly, in the absence of a deletion of an
allele, NMD-elicit mutations are still associated with a signiﬁcant
reduction of gene expression but at a lower magnitude
compared to cases when a deletion is present (Po2.2e 16,
MWW test, fold change¼ 0.43 and Po2.2e 16, MWW test,
fold change¼ 0.09, respectively, Supplementary Fig. 3b).
NMD-elicit mutations associated with hypermutation. Our
analysis, thus far, suggests that NMD-elicit mutations at TSGs
are associated with profound loss of expression because of asso-
ciated deletions of the wild-type allele. In contrast, NMD-elicit
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Figure 1 | The landscape of NMD-elicit mutations in cancer. (a) A diagram showing the three rules used to annotate NMD-elicit mutations.
(b) A schematic showing the pipeline used for the prediction of NMD-elicit mutations in TCGA data. (c) A summary of the number of NMD-elicit
mutations categorized by their original TCGA classiﬁcation as indicated. FSD, frameshift deletion; FSI, frameshift insertion; MM, missense mutation; NM,
nonsense mutation; Silent, silent mutation; IFD, in-frame insertion; IFI, in-frame insertion. (d) Boxplots comparing the expression levels of genes that
harbour NMD-elicit (green) and NMD-escape (red) frameshift indels and nonsense mutations. The horizontal line at 0.5 indicates no differential
expression. The expressions in the NMD-elicit group (N¼ 53,406) are signiﬁcantly lower than those in the NMD-escape (N¼ 19,773), non-PTC-
harbouring (N¼488,430) or silent (N¼ 202,508) groups (median ratio of REV¼0.54; ***Po2.2e 16, one-sided t-test). (e) Scatter plots showing the
correlation between the number of all mutations in a sample and the number of NMD-elicit mutations for each tumour type as indicated. The grey dashed
lines are the angle bisectors of the ﬁrst quadrants.
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mutations in non-TSG genes were associated with a modest loss
of expression and occurred at low frequency and are, therefore,
most probably associated with hypofunction of the affected gene.
While single mutations of that type are unlikely to have
important functional consequences, several mutations targeting a
particular pathway could collectively be selected for to promote
tumour survival. We tested this hypothesis in tumours with
hypermutation.
We identiﬁed six tumours that had frequent occurrence of
hypermutation and that were known to be frequently
associated with microsatellite instability (MSI). We identiﬁed
NMD-sensitive genes (with low z-scores) that were enriched in
NMD-elicit mutations in the hypermutated samples when
compared to other types of mutations such as silent mutation.
This analysis identiﬁed genes that were involved in DNA repair
such as MSH2, MSH6 and ASCC3 (Supplementary Data 2; false
discovery rate (FDR)o1e 06). Moreover, pathway enrichment
analysis identiﬁed DNA repair as one of the most signiﬁcantly
enriched pathways (Fig. 3a and Supplementary Data 3). In
addition, the analysis identiﬁed other pathways that appeared to
be enriched in NMD-elicit mutations in hypermutated samples.
For example, there was a signiﬁcant enrichment in NMD-elicit
mutations in genes involved in chromatin remodelling/
modiﬁcation, such as SMARCAD1, CHD1, CHD8, HDAC4,
BRD3 and TTF1 (FDRo5e 05). There was also an enrichment
in pathways involved in RNA binding and splicing. Most notably,
there were frequent NMD-elicit mutations in genes such as
LARP4B, YTHDC1 and EIF5B (FDRo5e 05 and Fig. 3).
These results suggest a possible requirement for suppression
of translation of mutated genes in hypermutated samples to
promote cancer cell survival. Further analysis revealed an
unexpected enrichment of NMD-elicit mutations in LARP4B
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Figure 2 | Tumour type-speciﬁc signatures for NMD-elicit mutations in tumour suppressor genes. (a) Boxplots showing the expression levels of the
indicated genes categorized by the type of mutations. NMD-elicit includes NMD-elicit frameshift insertions/deletions (indels) and nonsense mutations;
non-NMD includes frameshift and nonsense mutations that are not NMD-elicit. The genes harbouring NMD-elicit mutations have signiﬁcantly lower
expression than the genes harbouring non-NMD or missense mutations (median ratio of REV¼0.07 for NF1, 0.06 for TP53; Po2.2e 16, one-side MWW
test). The missense is the missense mutation. For TP53, the numbers in each group correspond to 39, 642 and 1,675. For NF1, the numbers in each group
correspond to 2, 171 and 177. (b) A barplot representation of the percentage of samples harbouring NMD-elicit TSGs (x axis) across cancer types (y axis).
(c) A heatmap indicating mutations of genes (rows) across samples (columns) as NMD-elicit (orange), non-NMD-elicit and non-silent (green) or others
(grey). Samples were organized by cancer type as indicated in the legend.
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(22/54 compared) and EIF5B (12/54) in hypermutated stomach
adenocarcinoma cases. Note that 25 out of 54 hypermutated cases
had NMD-elicit mutations of at least one of these two genes
(Fig. 3b). This indicated that suppression of translation was
particularly important in hypermutated STADs. Moreover, we
observed that 12 out of the 54 (22%) hypermutated STADs also
had PTEN NMD-elicit mutations. Compared to other cancers,
there was a signiﬁcant enrichment of NMD-elicit mutations in
the PTEN of hypermutated STADs (P¼ 4e 05).
Interestingly, 21 out of the hypermutated samples, that also
had high MSI, with NMD-elicit mutations in LARP4B occurred
because of deletion or insertion of a T at position chr10:890939,
hg19 in the LARP4B gene. As expected, NMD-elicit mutations in
LARP4B were associated with a modest but signiﬁcant
reduction in expression in STAD (median ratio of REV¼ 0.15,
FDR¼ 0.017, one-side MWW test). Similarly, 8 out of 12
NMD-elicit mutations in PTEN occurred because of a deletion
of an A (chr10:89717770-A, hg19). NMD-elicit mutations in
PTEN were associated with a profound and signiﬁcant reduction
in PTEN expression (median ratio of REV¼ 0.02, FDR¼ 8.7
e 05, one-side MWW test). To conﬁrm these results, we
analysed data from an independent study on STAD that
conducted whole-genome sequencing of 100 STADs13. This
revealed that 4 out of 10 cancers with MSI had mutations that
would induce PTCs in LARP4B and three of those mutations
occurred at the same site mentioned in TCGA data
(chr10:890939-T, hg19). Two out of the ten MSI samples had
frameshift mutations in EIF5B. For PTEN, there were three
cancers that had NMD-elicit mutation out of the ten MSI cancers
(Fig. 3c). These results indicate that NMD-elicit mutations in
these genes play a permissive role and are, therefore, potential
therapeutic targets for hypermutated STADs with MSI.
Discussion
Although the mechanisms and the rules of NMD have been
reported5,9, the full extent of its contribution to cancer initiation
and progression has remained unclear. In this work we
provide a systematic annotation of TCGA mutations as to
whether or not they are likely to induce NMD. We show a global
enrichment of NMD-elicit mutations in genes involved in DNA
repair, chromatin modiﬁcations and RNA stabilization in
hypermutated tumours. We speculate that this enrichment
plays a permissive role to allow the survival of cancer cells with
hypermutation and MSI. Our work suggests that investigations
into the therapeutic opportunities that target the dependence of
tumours on NMD-mediated LoF could lead to positive outcomes.
Previous annotations of frameshift and NMs do not allow the
clear identiﬁcation of whether or not a mutation is likely to elicit
NMD7,14. Our analysis used precise prediction of the PTC that
results from each of the mutations examined. This enabled a
large-scale re-annotation of mutations and revealed that only
two-third of nonsense and frameshift mutations can elicit NMD.
Our catalogue of NMD-elicit and NMD-escape mutations was
validated by demonstrating the signiﬁcant downregulation of
expression in only the predicted NMD-elicit group (Fig. 1d).
Interestingly, some in-frame and missense mutations were
predicted as NMD-elicit mutations, which suggests that
potential PTCs may be overlooked in these types of mutations.
We found that an in-frame mutation can result in the
approximation of nucleotides that result in a PTC. Similarly,
missense mutations occurring in the start codon can result in a
late-start codon that is out of the normal frame resulting in a
frameshift and, consequently, a PTC (see Methods).
We found that NMD-elicit mutations target certain TSGs
(for example, TP53 and NF1) across all cancer types, which is
Table 1 | Top NMD-affected genes in 24 cancers.
Cancer type (#samples) Top genes that frequently harbour NMD-elicit mutations (number of sample with its NMD mutants)
Adrenocortical (91) TP53 (6), DCP1A(5), MEN1 (5)
Bladder urothelial (396) KDM6A (69), ARID1A (62), TP53 (55), RB1 (48), STAG2 (39), TTNw (31), EP300 (23), FAT1 (23),
MUC16w (23) CDKN1A (22)
Breast-invasive (982) TP53 (93), MAP3K1 (68), CDH1 (64)
Cervical and endocervical (194) MUC4w (14), TTNw (12)
Colon (270) TTNw (49), APC (45), RNF43 (31), TP53 (26), BMPR2 (20), ZC3H13 (18), SYNE1 (17), ATM (16), ARID1A
(14), MBD6 (14), MUC16w (14) RYR2 (14)
Diffuse large B-cell lymphoma (48) TNFAIP3 (5), CIITA (4), ARID1A (3), HLA-A (3), SETD1B (3), SPEN (3), TET2 (3)
Oesophageal (184) TP53 (48), TTNw (11)
Glioblastoma ARHGAP5 (50), NF1 (17)
Head and neck squamous cell (512) TP53 (114), FAT1 (86), NSD1 (42), CDKN2A (41), NOTCH1 (33), TTNw (29)
Kidney clear cell (213) PBRM1 (62), CDC27 (18), FAM151A (17), OVGP1 (17), PHACTR1 (17), VHL (17), FANCE (16) DNMT1 (15),
GLI1 (15), MSI1 (14)
Brain lower-grade glioma (516) ATRX (45)
Liver hepatocellular (373) TP53 (32) APOB (19)
Lung (543) TP53 (65), TTNw (45), CSMD3 (33), MUC16w (33), LRP1B (31), STK11 (30) XIRP2 (28)
Lung squamous cell (178) TP53 (32), TTNw (26), CSMD3 (19), MUC16w (12), FAT1 (11)
Ovarian (374) TP53 (42)
Pancreatic (150) TP53 (26), SMAD4 (13), CDKN2A (11)
Rectum (116) APC (20), TTNw (16), TP53 (15), FBXW7 (9) MAL2 (6), VPS13C (6)
Sarcoma (259) ATRX (30), TP53 (24), RB1 (21)
Skin cutaneous melanoma (472) TTNw (102), NF1 (49), DNAH5w (44), ARID2 (37), MUC16w (35), LRP1B (34), DNAH7 (26), TP53 (26)
DCC (25), DNAH8 (24)
Stomach (289) ARID1A (57), RNF43 (56), TTNw (55), TP53 (44) BZRAP1 (33), XYLT2 (27), LARP4B (23), MBD6 (23),
ZC3H13 (22), PLEKHA6 (19)
Uterine corpus endometrioid (248) PTEN (96), TTNw (66), ARID1A (53), PIK3R1 (44), CTCF (30), MUC16w (21), FAT1 (20), ZFHX3
(20), DNAH11w (18) MKI67 (18)
NMD, nonsense-mediated decay.
Note: only the top 10 genes most frequently affected by NMD-elicit mutations are shown for each cancer. Three cancers (KIRP, PRAD and THCA) do not have top NMD-affected genes deﬁned in
Methods.
COSMIC-annotated cancer drivers.
wPotential false-positive cancer-associated genes.
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consistent with previous studies15–17. Interestingly, we found that
the magnitude of associated reduction in expression is higher in
TSGs compared with other genes. In other words, the NMD-elicit
mutations are associated with a more signiﬁcant decline in the
expression of TSGs. One possible explanation is that TSGs, as we
observed, tend to have one allele deleted and the other one
harbouring NMD-elicit mutations (Supplementary Fig. 3a),
which is in line with the two-hit hypothesis for TSGs18.
However, whether, on a global scale, NMD-elicit mutations
occur more frequently than other LoF mutations is difﬁcult to
Pathway affected by NMD-elicit mutations
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predict. This is because it is difﬁcult to conclude whether or not a
non-synonymous mutation results in LoF without conducting
functional studies. We speculate that NMD-elicit mutations would
occur less frequently than other LoF mutations in some genes such
as TP53, but that they are associated with signiﬁcant LoF because
of reduction in expression particularly in TSGs. The association
between NMD-elicit mutations in TSGs and the very low
expression level further supports the viewpoint that NMD is a
promising target for cancer treatment. Recent work into the
mechanisms of NMD regulation has provided feasible
approaches4,19–21 for the inhibition of NMD22–25. The aim of all
these approaches is to restore the expression of full-length genes
that harbour NMD-elicit mutations26 by ‘reading through’ the
PTC. We also found evidence of tumour type-speciﬁc targeting of
driver TSGs by NMD (Table 1), suggesting that therapeutic
targeting of NMD could be successful in a wide range of tumours.
In addition, inhibition of NMD can result in the expression of new
antigenic epitopes and enhanced antitumour immune response27.
However, other complexities need to be considered. For example,
the read-through product that is generated from a PTC-harbouring
transcript may result in a negative-dominant effect or other
deleterious impacts. It is noteworthy that certain tumours (UCEC,
BLCA and STAD) appear to have a higher load of NMD-elicit
mutations, suggesting that they may be particularly sensitive to
therapeutic targeting of NMD. Whether this higher load of
NMD-elicit mutations is the result of speciﬁc mutational signatures
that occur in these particular tumours is testable in future studies.
In addition, further analysis of the impact of cancer-speciﬁc
mutational partterns28 and signatures on potential enrichment of
NMD-elicit mutations in particular pathways might provide
important insights into the possible dependencies of these
tumours on NMD.
We observed that NMD-elicit mutations in ‘cancer-unrelated’
genes caused a modest reduction in expression but clustered in
particular pathways presumably to permit the emergence of
certain tumour phenotypes. This is reminiscent to the concept of
BRCAness29, where the dysfunction of many different genes can
perturb homologous recombination repair in a relatively large
proportion of patients. We found that DNA repair, chromatin
remodelling and RNA-binding pathways are preferentially
targeted by NMD-elicit mutations in hypermutated samples.
Given the known role that DNA repair and chromatin
remodelling genes play in regulating response to DNA damage,
it is plausible to suggest that this enrichment acts in a permissive
capacity to enable the establishment and survival of
hypermutated cancer cells30. Moreover, we found that stomach
adenocarcinoma (STAD) tends to have disproportionately higher
number of NMD-elicit mutations and a mutator phenotype that
selects for NMD-elicit mutations in LARP4B, EIF5B and PTEN.
Although the potential relationship between LARP4B or EIF5B
and cancer has been previously reported31–34, the link between
these genes and hypermutation was previously unrecognized. It is
conceivable that NMD-mediated hypofunction of LARP4B or
EIF5B permits the hypermutated cancer cells to cope with a high
mutation load by delaying translation.
Although the rules that we used to predict NMD-elicit
mutation are known to have a signiﬁcant effect on mRNA levels,
other potentially important factors may have been overlooked
because of the incomplete understanding of the mechanisms of
NMD in humans. For example, the potential role of insertions
and deletions in the 30 untranslated repeat (UTR) in inducing
NMD has remained unclear. Whether or not mutations in
members of the NMD complex may have an impact on eliciting
NMD is difﬁcult to study on a global scale because of the low
number of mutations in this complex and the lack of clarity as to
whether any particular mutation in this complex is associated
with LoF. In addition, our results do not take into account the
potential suppression of NMD by the tumour microenvironment
as recently reported35,36. Other than NMD-elicit mutations,
mutations occurring in transcription factors, epigenetic factors
and non-coding mRNAs may affect mRNA levels. Another
unaddressed question is the relationship between the mRNA level
and the combination of allelic ratio, allele-speciﬁc expression and
the prevalence of a mutation. The future application of advanced
sequencing technologies, and the development of novel
computational models would enable further detailed analyses of
the effect of a mutation on gene expression.
In summary, we provide a comprehensive annotation of NMD
in all mutations reported by TCGA. Our work unravels
unrecognized dependencies of tumours on NMD-mediated LoF
with potential therapeutic opportunities37–41.
Methods
Data pre-processing. The following four ﬁles, RNA-seq data (tcga_RSEM_Hu-
go_norm_count, 2016-02-18), somatic mutations annotation ﬁle (MAF, 2016-04-28)
for results of DNA sequencing, CNV data (Gistic2_CopyNumber_Gistic2_all_-
thresholded.by_genes, 2016-08-16) and clinical data (PANCAN_clinicalMatrix,
2016-04-30, were downloaded from the ‘TCGA Pan-Cancer (PANCAN)’
cohort at the TGCA hub and the GA4GH-BD2K (TOIL) hub on USCS Xena
(https://xenabrowser.net)42. The TCGA Pan-cancer RNA-seq data contained
normalized and log-transferred counts, which were quantiﬁed by RSEM43. We
downloaded the non-negative matrix factorization (NMF) cluster data (Version
2016_01_28) from the Broad GDAC Firehose (http://gdac.broadinstitute.org)44,
which clustered samples based on mRNA-seq data. To obtain sufﬁcient samples for
adequate statistical analysis, we only analysed the 24 cancer types that had more than
10,000 somatic mutations in total.
Prediction algorithm of NMD-elicit mutations. We retrieved the coding
sequences (CDSs) and positional annotations of transcripts provided by UCSC
(hg19, Feb. 2009) via the R interface. The canonical isoform was deﬁned as the one
with the longest CDS. For each gene, we extracted the positional information from
the TxDb package and the longest CDS from the BSgenome package, based on the
reference genome (hg19/NCBI Build 37). The positional information included the
chromosomal start and stop positions of exons. We calculated the relative positions
of exon–exon junctions and the relative position of mutations on the CDSs.
Figure 3 | Hypermutated tumours are enriched in NMD-elicit mutations targeting hypermutation-permissive pathways. (a) The barplot in the top panel
shows the numbers of the different types of mutations (y axis) in each sample (x axis). The heatmap in the bottom panel shows the cancer type (cancer),
whether a sample is hypermutated or not (hypermutation), log 10 of total mutation numbers (log 10 mutation frequency), whether a sample is
microsatellite-stable or not (microsatellite stability), the NMD-elicit mutations in individual relevant genes and their pathway afﬁliation as indicated and the
pathways affected by NMD-elicit mutations (black means that the pathway has at least one gene harbouring NMD-elicit mutations) in each sample
(x axis). (b) In STAD, the heatmap shows the log 10 of total mutation numbers (ﬁrst row), MSI (second row), the NMD-elicit mutations in individual
relevant genes (3rd–7th rows) and NMD-elicit mutations in genes that belong to certain pathways (8th–10th rows) in each sample (x axis). FS, frameshift
indels; IF, in-frame indels; SN, single-nucleotide substitution mutations. (c) In gastric cancer validation cohort13, the heatmap in the bottom panel shows the
log 10 of total mutation numbers (ﬁrst row), MSI (second row), the NMD-elicit mutations in individual relevant genes (3rd–7th rows) and NMD-elicit
mutations in genes that belong to certain pathways (8th–10th rows) in each sample (x axis). FS, frameshift indels; IF, in-frame indels; SN, single-nucleotide
mutations. Del, deletions; Ins, insertion; SN, substitution mutations. Note that the NMD-escape mutations in EIF5B and LARP4B are likely to induce NMD as
they failed the NMD rules only marginally. Both EIF5B NMD-escape mutations failed the rules because they generate PTCs that are 175 bp away from the
start codon. The LARP4B mutations generate a PTC that is 187 bp away from the start codon.
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Combining the mutation data from TCGA and the wild-type CDSs gave the
mutated sequences. For this analysis, we have excluded 22 genes with PTCs in the
wild-type sequence, mutations that occur on the splice sites or on the exon–intron
junctions not annotated by TCGA, mutations where the reference allele does not
match the nucleic acid on the reference genome, 32 genes with CDS that do not
start with start codons, which may be incorrectly annotated, and 47 genes starting
with start codon but without in-frame stop codon. The reason for the ﬁrst criteria
is that the mRNA may have strong second structure where the NMD fails. The
reason for the second criteria is that the splice-site mutations may induce alter-
native splicing, which affects mRNA levels in a complex way. The third criterion is
to exclude the possible incorrect mutation annotation.
Our algorithm ﬁrst detected all possible start codons (ATA and ATG) and stop
codons (TGA, TAA and TAG) in their mutated sequences. Among all of the
possible start codons, the most upstream one was denoted as the putative start
position. The stop position was selected by the two criteria. The ﬁrst one is that the
stop codon is in the same frame as the start codon, because the CDS must be
the multiples of three. The second one is that the stop position is the closest one to
the start codon among all the candidates.
On the basis of the predicted relative positions of the stop codon and the last
exon–exon junction in the variant, the classiﬁcation of NMD was conducted by
three rules, that the gene has at least two exons, that the stop codon in the variant is
more than 50 bp upstream from the last exon–exon junction and that the PTC is
more than 200 bp downstream from the start codon. If the mutation satisﬁed the
above rules, the mutation was classiﬁed into the NMD-elicit mutation; otherwise,
into NMD-escape mutations that generate PTCs, or non-PTC mutations.
In addition to the aforementioned ﬁltering, the certain types of mutations were
also excluded from analysis. The ﬁrst type is the mutations of genes without Entrez
gene IDs or with multiple corresponding Entrez gene IDs. The second type is the
repeated annotations of the same mutations, but multiple mutations within one
gene in one sample are retained to avoid underestimation of NMD effect. The third
type includes the mutations with TCGA annotation as ‘Splice_Site’, ‘30UTR’,
‘50UTR’, ‘IGR’, ‘Intron’ and ‘RNA’.
Novel annotation compared to TCGA. We detected NMD-elicit mutations from
the missense mutations, NMs, silent mutations, nonstop mutations, mutations on the
translation start site, in-frame indels and frameshift indels annotated by TCGA. We
compared our prediction results (NMD-elicit mutations versus others) with the original
TCGA annotations (Fig. 1c). We validated unexpected results, such as reclassifying in-
frame indels or missense mutations to NMD-elicit mutations by performing manual
checks. Supplementary Fig. 4 gives examples of how in-frame indels or missense
mutations can potentially elicit NMD. We measured the correlation between total
mutations and NMD-elicit mutations by Pearson correlation and identiﬁed the cancers
with higher NMD-elicit mutated rate by generalized linear regression on cancer types.
Expression-based analysis on NMD impact. Statistical test. We compared the
expression levels using the nonparametric MWW test (wilcox.test in R) or the
t-test. The MWW tests and t-tests without the statement of one-sided are
two-sided.
Calculation of REV. To validate the impact of NMD-elicit mutations on the
expression levels, we calculated the relative expression of variant to mask the gene-
speciﬁc effect for each mutation, including NMD-elicit and other mutations. The
relative expression was deﬁned by the rank of the expression level of the variant
(the gene with a mutation) in its background expression. The gene-and-cancer-
speciﬁc background expression was deﬁned as the expression levels of a gene from
these samples from the same cancer, which have no somatic mutations or CNV
and belong to the same NMF cluster (Broad ﬁrehose) or from the same cancer if
the NMF clustering was absent. For example, in J total samples, gene i has
NMD-elicit mutations in m samples (1Bm), and does not have NMD-elicit
mutations in the other n samples (mþ 1Bmþ n). Denote ei,j as the expression
level of gene i in sample j, E¼ ei,mþ nþ 1,ei,mþ 2þ 2, ei,j as the background
expression. The REV of each mutation of gene i in sample m can be calculated by
REVi;m ¼ Ri;m  1sizeðEÞ ; sizeðEÞ ¼ J m n, where the size(E) denotes the number of
wild-type samples from the same cancer and the Ri,m denotes the ranking of ei,m in
the background expression level. The lower the relative expressions of variant, the
larger the downregulation of expression of the variant. We compared the relative
expression of predicted NMD-elicit mutations with the NMD-escape or non-PTC
mutations in the frameshift deletions, frameshift insertions and NMs, by the one-
side MWW test (wilcox.test in R).
Annotation of TSGs and cancer-speciﬁc NMD signature. The list of cancer-
related genes and TSGs was downloaded from COSMIC (http://cancer.sanger.-
ac.uk/census)12. The number of studied TSGs is 71. The 127 SMGs were reported
by pan-cancer mutation analysis11. We deﬁned the top NMD-affected genes for
each cancer as the genes harbouring NMD mutations within over 5% samples. We
marketed genes that are potential false-positive cancer-associated genes, such as
TTN and MUC16 (ref. 28; Table 1).
Quantifying gene-speciﬁc NMD-associated reduced expression. To mask the
NMD-insensitive genes that do not show decrease in their expression even with
NMD-elicit mutations, we deﬁned and calculated the z-score based on the U
statistic in the nonparametric MWW test. Every gene in each cancer had its gene-
speciﬁc and cancer-speciﬁc z-score. For each gene, we extracted the expression
levels of its NMD-elicit mutants and the levels of its predeﬁned wild type. To
calculate the valid statistic, we discarded the gene with less than three NMD-elicit
mutations. We denoted N1 as the number of samples with the wild type of gene,
and N2 as the number of samples with NMD-elicit mutations in this gene. We
ranked all the expression levels in two groups and calculated the sum of ranks
(denoted as U1 and U2) for each group separately. The z-score is the statistic U
normalized by N1 N2, which ranges from 0 to 1.
U1 ¼ sum rank N1ðN1 þ 1Þ2
U2 ¼ sum rank N2ðN2 þ 1Þ2
U ¼ minðU1;U2Þ
The lower z-score means the more decreased expression of the genes that harbours
NMD-elicit mutations. The z-scores no less than 0.5 means the magnitude of NMD-
associated reduction in expression is negligible in this gene. On the basis of z-scores,
we classiﬁed genes into NMD-sensitive genes (z-scoresr0.3), intermediate (0.3oz-
scoresr0.4) and NMD-insensitive ones (z-scores 40.4),
NMD-elicit mutations in hypermutation. We deﬁned hypermutated samples as
the ones with over 1,000 ﬁltered mutations. The non-hypermutated samples were the
ones with less than 100 ﬁltered mutations. BLCA, COAD, LUAD, SKCM, STAD and
UCEC had more than 30 hypermutated samples and were used for further analysis.
The MSI data were downloaded from previous pan-cancer analysis45.
To quantify the gene-speciﬁc enrichment in NMD-elicit mutations in
hypermutated samples, we calculated the normalized ratio between NMD-elicit
mutations and silent mutations (‘Silent’, ‘3’ UTR’, ‘5’ UTR’, ‘Intron’, ‘RNA’)
between the hypermutated and non-hypermutated samples. We calculated the
P value by Fisher exact test, adjusted by FDR. The ratio can measure the
enrichment of NMD in hypermutation. It was normalized by the total number of
each mutation type to mask the negative selection on the NMD-elicit mutations.
To identify important pathways or molecular functions, we took the signiﬁcantly
enriched NMD-sensitive genes (FDRo0.05) as the input for the gene ontology
enrichment analysis (top GO in R) by the classic and weighted algorithm. The
validation data set was from an independent data set13 other than the TCGA data.
Data availability. The pan-cancer data and the computer codes that support the
ﬁndings of this study are available in GitHub (https://github.com/ZYBunnyHu/
NMD-paper) without restriction. The R package for predicting NMD-elicit
mutations, masonmd (Make Sense of NMD), are available in GitHub with the
identiﬁer (DOI: 10.5281/zenodo.546698)46.
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